TABLE 1.
Cytotoxicity in human cell lines after 5-day treatment
| Base | Compound | Mean CC50 ± SD (μM) in: |
||||
|---|---|---|---|---|---|---|
| Hepatic cells |
Prostate cells (PC-3) | Fibroblasts (MRC5) | T-cells (MT-4) | |||
| Huh7 | HepG2 (galactose) | |||||
| Uridine | Sofosbuvir | 66 ± 17 | >89 | >100 | >89 | >100 |
| Guanosine | IDX184 | >89 | >89 | 77 ± 14 | >89 | 66 ± 18 |
| BMS-986094 | 0.5 ± 0.2 | 1.9 ± 1.0 | 1.0 ± 0.2 | 1.1 ± 0.3 | 1.1 ± 0.5 | |
| PSI-938 | >89 | >89 | >100 | >89 | >100 | |
| Cytidine | PSI-6130 | >89 | >89 | >100 | >89 | >100 |
| 4′-AzidoC | >89 | >89 | 30 ± 6 | >89 | >100 | |
| 2′CMeC | >89 | >89 | 49 ± 18 | 69 ± 1 | 19 ± 6 | |
| Adenosine | GS-6620a | 67 ± 13 | 66 ± 13 | 40 ± 0.7 | 8.9 ± 4.1b | 7.8 ± 4.3b |
| ddCc | >89 | >89 | 0.80 ± 0.21 | >89 | >89 | |
| Chloramphenicolc | >89 | >89 | 16 ± 3 | >89 | >89 | |
| Αlpha-amanitinc | 0.45 ± 0.16 | 0.81 ± 0.35 | 0.17 ± 0.06 | 0.34 ± 0.07 | 0.89 ± 0.10 | |
| Puromycinc | 0.52 ± 0.19 | 0.65 ± 0.18 | 0.22 ± 0.07 | 0.24 ± 0.05 | 0.16 ± 0.06 | |
a
The cytotoxicity of GS-6620 in some cell types was reported previously (13).
b
Complex, multiphasic dose response was observed, with an initial drop in viability of 50% followed by a rebound to over 50% at higher concentrations. Flow cytometry studies suggested that the effect of the compound on these cells was cytostatic instead of cytotoxic.
c
Control treatment.